CADx Systems has received approval from the FDA for its Second Look Digital and Second Look AD computer-aided detection systems. The approval paves the way for the technologies to be integrated with GE's Senographe 2000D full-field digital mammography
CADx Systems has received approval from the FDA for its Second Look Digital and Second Look AD computer-aided detection systems. The approval paves the way for the technologies to be integrated with GE's Senographe 2000D full-field digital mammography system. Approval of the Second Look Digital CAD also allows an immediate upgrade path for mammography sites to integrate analog and digital CAD processing with the Second Look AD, which allows simultaneous processing of analog and digital mammography images.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.
Multicenter Study Identifies Key Factors Associated with Mammogram-Occult Ipsilateral Breast Cancer
October 9th 2024A symptomatic first breast cancer diagnosis, prevailing breast density at a second breast cancer diagnosis and trabecular thickening on surveillance mammography were linked to mammogram-occult ipsilateral breast cancer, according to new research.
Radiology Experience, Breast Density and Screening Mammography: What New Research Reveals
October 4th 2024In a study looking at the impact of experience and case volume of breast screening radiologists, researchers found that reviewing more than 150 cases per week was necessary to achieve an 80 percent rate of true-positive assessments for malignant calcifications.